The arrival of Retatrutide in the UK is sparking significant anticipation within the weight management community. This novel dual compound – targeting both GLP-1 and GIP – promises a remarkably new approach to combating obesity . As of now , options have been constrained for many, and Retatrutide signifies a encouraging opportunity for patients